Cytosorbents Corporation (CTSO)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 0.8217 |
| Open | 0.8201 |
| Bid | 0.7695 x 100 |
| Ask | 0.8526 x 100 |
| Day's range | 0.8010 - 0.8630 |
| 52-week range | 0.7820 - 4.2900 |
| Volume | |
| Avg. volume | 100,938 |
| Market cap | 43.934M |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings date | 30 Apr 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.70 |
GlobeNewswireSTAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation a
Simply Wall St.These Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under Threat
The analysts covering Cytosorbents Corporation ( NASDAQ:CTSO ) delivered a dose of negativity to shareholders today, by...
Simply Wall St.Cytosorbents Full Year 2023 Earnings: Misses Expectations
Cytosorbents ( NASDAQ:CTSO ) Full Year 2023 Results Key Financial Results Revenue: US$36.3m (up 4.8% from FY 2022). Net...
© 2024 Yahoo. All rights reserved.